IL313966A - Methods for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compounds - Google Patents
Methods for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compoundsInfo
- Publication number
- IL313966A IL313966A IL313966A IL31396624A IL313966A IL 313966 A IL313966 A IL 313966A IL 313966 A IL313966 A IL 313966A IL 31396624 A IL31396624 A IL 31396624A IL 313966 A IL313966 A IL 313966A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- reaction
- added
- solvent
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111658903.5A CN114213424B (zh) | 2021-12-30 | 2021-12-30 | 一种呋喃[3,2-b]并吡啶衍生物的合成方法 |
| PCT/CN2022/139966 WO2023125102A1 (zh) | 2021-12-30 | 2022-12-19 | 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313966A true IL313966A (en) | 2024-08-01 |
Family
ID=80707144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313966A IL313966A (en) | 2021-12-30 | 2022-12-19 | Methods for synthesizing 1h-furo[3,2-b]imidazo[4,5-d]pyridine compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250171458A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4509509A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024546195A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240129021A (cg-RX-API-DMAC10.html) |
| CN (2) | CN114213424B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022426316A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3244846A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL313966A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024008276A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023125102A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201990523A1 (ru) | 2016-10-03 | 2019-10-31 | НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ | |
| CN114213424B (zh) * | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3,2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| CN121949334A (zh) * | 2024-10-30 | 2026-05-01 | 谱尼生物医药科技(上海)有限公司 | 一种医药中间体7-羟基呋喃并[3,2-b]吡啶的合成方法及其中间体化合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039146A1 (en) * | 2005-09-23 | 2007-04-12 | Smithkline Beecham Corporation | 4-carboxy pyrazole derivatives as anti-viral agents |
| WO2011138657A1 (en) * | 2010-05-04 | 2011-11-10 | Glenmark Pharmaceuticals S.A. | Aryl substituted olefinic compounds as pde10a inhibitors |
| WO2013051672A1 (ja) * | 2011-10-04 | 2013-04-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
| CN103450125B (zh) * | 2013-07-18 | 2016-01-13 | 嘉兴中科化学有限公司 | 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法 |
| EP2940022B1 (en) * | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridines as inhibitors of protein kinases |
| CN105418620B (zh) * | 2014-09-23 | 2018-05-04 | 天津药明康德新药开发有限公司 | 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法 |
| WO2016100349A2 (en) * | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| WO2016196244A1 (en) * | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| CN106432232A (zh) * | 2016-09-18 | 2017-02-22 | 苏州汉德创宏生化科技有限公司 | 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法 |
| EA201990523A1 (ru) * | 2016-10-03 | 2019-10-31 | НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ | |
| CN107216334A (zh) * | 2017-06-29 | 2017-09-29 | 上海吉尔多肽有限公司 | 一种6‑氯呋喃[3,2‑b]吡啶的合成方法 |
| MX2021014319A (es) | 2019-06-06 | 2022-01-26 | Highlightll Pharmaceutical Hainan Co Ltd | Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo. |
| EP4393492A3 (en) | 2019-06-06 | 2024-08-07 | Hangzhou Highlightll Pharmaceutical Co., Ltd. | Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt |
| EP3967694A4 (en) * | 2019-06-06 | 2022-12-07 | Beijing Tide Pharmaceutical Co., Ltd. | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR-KINASE INHIBITOR |
| WO2021061803A1 (en) * | 2019-09-23 | 2021-04-01 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| CA3162572A1 (en) * | 2019-11-27 | 2021-06-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tri-heterocyclic compound as jak inhibitor, and use thereof |
| CN114213424B (zh) * | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3,2-b]并吡啶衍生物的合成方法 |
-
2021
- 2021-12-30 CN CN202111658903.5A patent/CN114213424B/zh active Active
-
2022
- 2022-12-19 JP JP2024539899A patent/JP2024546195A/ja active Pending
- 2022-12-19 US US18/725,431 patent/US20250171458A1/en active Pending
- 2022-12-19 EP EP22914356.5A patent/EP4509509A4/en active Pending
- 2022-12-19 CA CA3244846A patent/CA3244846A1/en active Pending
- 2022-12-19 IL IL313966A patent/IL313966A/en unknown
- 2022-12-19 CN CN202280087204.6A patent/CN118679166A/zh active Pending
- 2022-12-19 KR KR1020247025635A patent/KR20240129021A/ko active Pending
- 2022-12-19 AU AU2022426316A patent/AU2022426316A1/en active Pending
- 2022-12-19 MX MX2024008276A patent/MX2024008276A/es unknown
- 2022-12-19 WO PCT/CN2022/139966 patent/WO2023125102A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4509509A4 (en) | 2026-06-03 |
| WO2023125102A1 (zh) | 2023-07-06 |
| CA3244846A1 (en) | 2025-06-13 |
| CN114213424A (zh) | 2022-03-22 |
| CN114213424B (zh) | 2023-05-26 |
| US20250171458A1 (en) | 2025-05-29 |
| JP2024546195A (ja) | 2024-12-17 |
| KR20240129021A (ko) | 2024-08-27 |
| MX2024008276A (es) | 2024-09-02 |
| EP4509509A1 (en) | 2025-02-19 |
| AU2022426316A1 (en) | 2024-07-25 |
| CN118679166A (zh) | 2024-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3244846A1 (en) | PROCESS FOR THE SYNTHESIS OF A 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND | |
| JP7855657B2 (ja) | フロイミダゾピリジン化合物、多形物質および塩の多形物質の合成方法 | |
| EP4074710A1 (en) | Pyrazolo[1,5-a]pyridine compound, preparation method therefor and use thereof | |
| NZ530992A (en) | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | |
| CN116731046B (zh) | 一种高活性的hpk1激酶抑制剂 | |
| CN115991703A (zh) | 并环化合物及其制备方法、药物组合物和应用 | |
| AU2012253237A1 (en) | Methods for preparing naphthyridines | |
| KR20240100424A (ko) | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 | |
| AU2014219754B2 (en) | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method | |
| CN109563097B (zh) | 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法 | |
| CN117645598A (zh) | 氮杂二并多元稠环化合物及其药物组合物和应用 | |
| EP3927689B1 (en) | Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | |
| Seck et al. | Synthesis of new selenophene and thiazole analogues of the Tacrine series | |
| CA3214116A1 (en) | A crystal form of a fluorine-substituted pyridopyrazole compound and a preparation method thereof | |
| CN108658981A (zh) | 一种6-溴-4-甲氧基氢-吡唑[1,5-a]吡啶-3-甲腈的合成方法 | |
| EP3549935A1 (en) | Method for producing triazine compound | |
| CN120383608A (zh) | 三环化合物的盐、其晶型及其应用 | |
| CA3149179C (en) | Process for the synthesis of the sodium salt of 4-[[(1r)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2h)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | |
| CN119320386A (zh) | 一类mettl3抑制剂、其制备方法及其应用 | |
| EA049981B1 (ru) | Способ синтеза фуроимидазопиридинового соединения, полиморфного вещества и полиморфа соли | |
| JP6997769B2 (ja) | 2-(6-ニトロピリジン-3-イル)-9H-ジピリド[2,3-b;3’,4’-d]ピロールの製造方法 | |
| EP4588918A1 (en) | Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one | |
| CN115785089A (zh) | 一种利奥西呱杂质c的合成方法 | |
| CN118772149A (zh) | 利格列汀杂质8的合成方法 | |
| EA051348B1 (ru) | Способ синтеза фуроимидазопиридинового соединения, полиморфного вещества и полиморфа соли |